Phil Pang, M.D., Ph.D.
Chief Medical Officer
Phil Pang, M.D., Ph.D., is the Chief Medical Officer at Vir. Previously, he served as the chief medical officer at Riboscience, a biotech startup developing small molecule antivirals. Prior to Riboscience, he was with Gilead Sciences, Inc. where he successfully led the 100+ matrix team responsible for the worldwide approval of the hepatitis C blockbuster treatment, Harvoni (sofosbuvir/ledipasivir), and the subsequent filing of eight subsequent supplemental NDAs/Type II variations expanding the patient population eligible for this treatment.